1. Liuweiwuling Tablet relieves the inflammatory transformation of hepatocellular carcinoma by inhibiting the PI3K/AKT/NF-κB signaling pathway.
- Author
-
Chen, Yuanyuan, Song, Zheng, Hou, Xiaorong, Liu, Jia, Zheng, Congyang, Zhao, Xiaomei, Lv, Guiji, Li, Junjie, Xiu, Ye, Shi, Wei, Zhao, Jia, Yang, Huijie, Wang, Yan, Zhao, Jun, Zhan, Xiaoyan, Niu, Ming, Zou, Wenjun, Bai, Zhaofang, and Xiao, Xiaohe
- Subjects
- *
BLOOD testing , *ALKALINE phosphatase , *GAMMA-glutamyltransferase , *FLOW cytometry , *HERBAL medicine , *IN vivo studies , *STAINS & staining (Microscopy) , *SEQUENCE analysis , *ANIMAL experimentation , *NITROSOAMINES , *WESTERN immunoblotting , *NEOPLASTIC cell transformation , *HEPATITIS , *NF-kappa B , *MACROPHAGES , *CIRRHOSIS of the liver , *APOPTOSIS , *CELLULAR signal transduction , *RATS , *SEVERITY of illness index , *GENE expression , *TRANSFERASES , *GENE expression profiling , *ENZYME-linked immunosorbent assay , *CELL proliferation , *INFLAMMATORY mediators , *CELL lines , *POLYMERASE chain reaction , *PHARMACEUTICAL chemistry , *CALCIUM-binding proteins , *CHINESE medicine , *HEPATOCELLULAR carcinoma , *ASPARTATE aminotransferase , *ALANINE aminotransferase , *PHARMACODYNAMICS , *DISEASE risk factors - Abstract
Liuweiwuling Tablet (LWWL) is a patented Chinese medicine approved by the Chinese National Medical Products Administration (NMPA). Clinically, it is used to treat a range of liver diseases that precede hepatocellular carcinoma (HCC), including hepatitis, liver fibrosis and cirrhosis. LWWL is hypothesized to inhibit the inflammatory transformation of HCC, which may have a positive impact on the prevention and treatment of HCC. However, its exact mechanism of action remains unknown. To investigate how LWWL is effective in the treatment of HCC and to validate the pathways involved in this process. An in vivo model of HCC induced by diethylnitrosamine (DEN) was established to study the effect of LWWL on the development of HCC. The rat serum was analyzed for aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and gamma-glutamyl transpeptidase (γ-GT). The rat liver tissues were stained with hematoxylin and eosin (HE) and Masson's trichrome for pathological analysis. Rat liver tissue was subjected to transcriptome sequencing. Expression of inflammatory and liver fibrosis-related factors in bone marrow-derived macrophages (BMDMs) and LX-2 cells was detected by QRT-PCR, ELISA and Western blot (WB). The expression of apoptosis and stemness genes in HepG2 and Huh7 cells was assessed through flow cytometry and QRT-PCR. Transcriptomics, network pharmacology, WB, and QRT-PCR were employed to validate the mechanisms associated with the amelioration of HCC development by LWWL. LWWL significantly reduced the severity of hepatitis and liver fibrosis, the expression of tumor stemness genes, and the incidence of HCC. In addition, LWWL inhibited the release of inflammatory substances and nuclear accumulation of P65 protein in BMDMs as well as the conversion of LX-2 cells to fibroblasts. LWWL inhibited the proliferation of HepG2 and Huh7 cells, including the initiation of apoptosis and the reduction of stemness gene expression. Importantly, LWWL regulates the PI3K/AKT/NF-κB pathway, which affects hepatic inflammation and cancer progression. LWWL inhibited the occurrence and development of HCC by modulating the severity of hepatitis and liver fibrosis, indicating the potential clinical relevance of LWWL in preventing and treating HCC. [Display omitted] • Potential efficacy of LWWL in chemically related hepatocellular carcinoma. • LWWL inhibits the development of the hepatitis-fibrosis-HCC axis. • A key mechanism of LWWL is the PI3K/AKT/NF-κB signalling pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF